Merck's Keytruda wins melanoma OK in Europe; Pfizer plots R&D base in Cambridge, MA; Abbott's generic sales shine;

@FiercePharma: Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar. FiercePharmaMarketing report | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Horizon hikes Depomed offer to $2B in bid for 'friendly' deal talks. Report | Follow @CarlyHFierce

> Merck & Co.'s ($MRK) Keytruda nabbed European approval for use in advanced melanoma patients, both previously untreated and previously treated, in the ongoing push for market share in cancer immunotherapies. Release

> Pfizer ($PFE) is expanding its R&D presence in Cambridge, MA, with plans to put 1,000 staffers in the biotech hub around Kendall Square. Report

> Abbott Laboratories ($ABT) beat second-quarter profit estimates, partly because of strong generic drug sales, which rose 31% on a buyout of Chile's CFR Pharmaceuticals last year. Report

> GlaxoSmithKline ($GSK) sued Tibco Software, claiming the California-based company used its proprietary information to develop a risk-based monitoring tool that it's now selling as a custom software package. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Implanting a titanium tube inside damaged bones improves procedure to ward off amputations. Story | Follow @FierceMedDev

@EmilyWFierce: A U.K. research firm is developing tech to make diagnostic tests with an inkjet printer. More from the BBJ | Follow @EmilyWFierce

> iHealth expands its retail, connected medical device empire and looks to move into corporations, hospitals. Article

> Propeller Health receives FDA clearance to sell its app and sensor to patients using Glaxo's inhalers. More

> Bloomberg: St. Jude Medical discussing takeover of Thoratec. Report

Biotech News

@FierceBiotech: ICYMI: 'Cures' bill, designed to speed drug approvals, could be too much of a good thing, dissenters say. Story | Follow @FierceBiotech

@JohnCFierce: Schoenebaum sees great stuff in $BIIB data, predicts a rise in share price. | Follow @JohnCFierce

@DamianFierce: $BIIB investigator declined to color in 54-week 6mg data with my pen but agreed there should be a lottery. Image | Follow @DamianFierce

> AstraZeneca's once-lauded drug flunks a Phase III eye cancer trial. More

> Xoma crushed as lead drug flunks a PhIII challenge. Article

> In a setback, Biogen's mid-range dose of aducanumab flops in Alzheimer's study. Story

> Roche brings an Alzheimer's drug back from the brink with another PhIII endeavor. News

> Eli Lilly offers evidence of twice-failed solanezumab's impact on Alzheimer's. Report

Biotech Research News

> Meta-analysis: Avandia's impact on Parkinson's should spur new research. Report

> Animal study highlights role of mast cells in chronic eye diseases. More

> Specialized cells in Alzheimer's could be used for diagnosis, drugs. Report

> Yale scientists highlight a promising eczema study for Pfizer's Xeljanz. Story

> NYU Langone team spotlights new antibodies for Alzheimer's, Parkinson's. Article

Diagnostics News

> Illumina launches new lab service for HiSeq X sequencing systems. More

> Alere revs up engine with new deals and win for quick strep test. Story

> Exact Sciences reveals $179M public offering amid slumping Q2 sales. News

> Oxford Nanopore reels in $109M to ramp up R&D. Item

> Theranos inks Medicaid deal and snags CLIA waiver to expand Dx reach. Article

Pharma Marketing News

> Will Genzyme's Fabry pill only steal sales from Fabrazyme? Not if it acts like Cerdelga. More

> Abbott boosts generic drug sales by 31% in strong Q2 showing. Item

> Sanofi Pasteur drafts Bollywood star to talk up flu shots in India. Report

> What's in a pill color? Consumers see messages in red, blue, green and white. Story

> The PCSK9 countdown: Amgen's Repatha wins EU race, with Sanofi's Praluent up Friday at FDA. Article

And Finally... More than one in 5 sexually active teen girls have used the morning-after pill, in a dramatic increase that may reflect that it's now easier for them to buy the emergency contraceptive, the AP reports. Story

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.